2Lip G Y,Blann A D. yon Willebrand factor: a marker of endothelial dysfunction in vascular disorder [-J] . Cardiovasc Res 1997,34(2) 255-265.
3Meyer B, Mortl D, Strecker K, et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure, comparison with B-type natriuretic pep- tide[J]. J A m CoU Cardiol,2005,46(6).1011-1018.
2Feener EP, Northrup JM, Aiello LP, et al. Anglotemin 2 induces plasminogen activator inhibitor- 1 and- 2 expreaaion in vascular endothelial and smooth muscle cells. J Clin Invest, 1995;95: 1353-1362.
3Catherin L, David E, Newby, et al. Fibrinolytic actions of intaarterial angiotensin Ⅱ and bradykinin in vivo in man. Cardiov Res,2000;47:707-714.
4Goodfield NE, Newby DE, Ludlam CA, et al. Effects of acute angiotensin Ⅱ type 1 receptor antagonisn and anglotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation, 1999;99(23) :2983-2985.
